Last update 21 Nov 2024

AXT1003

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
EZH2
Mechanism
EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [3]
Active Indication
Advanced Malignant Solid NeoplasmAdvanced cancerExtranodal NK-T-Cell Lymphoma+ [4]
Inactive Indication
Peripheral T-Cell Lymphoma
Originator Organization
Novartis AGNovartis AG
Active Organization
Axter Therapeutics (Tianjin) Co., Ltd.Axter Therapeutics (Tianjin) Co., Ltd.Axter Therapeutics (Beijing) Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with AXT1003
NCT06484985 / RecruitingPhase 1
An Open-label, Multicenter, Phase I Safety Study of AXT-1003 in Subjects With Advanced Malignant Tumors
CTR20242194 / RecruitingPhase 1
一项AXT-1003治疗晚期恶性肿瘤患者的开放标签、多中心、I期安全性研究
[Translation] An open-label, multicenter, phase I safety study of AXT-1003 in patients with advanced malignancies
NCT05965505 / TerminatedPhase 1
An Open-Label, Multicenter, Phase I Study of AXT-1003 as a Single Agent in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
100 Clinical Results associated with AXT1003
Login to view more data
100 Translational Medicine associated with AXT1003
Login to view more data
100 Patents (Medical) associated with AXT1003
Login to view more data
100 Deals associated with AXT1003
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
CN
Axter Therapeutics (Beijing) Co., Ltd.
04 Sep 2024
Advanced cancerPhase 1
CN
Axter Therapeutics (Beijing) Co., Ltd.
30 Jul 2024
Extranodal NK-T-Cell LymphomaPhase 1
CN
Axter Therapeutics (Beijing) Co., Ltd.
-
Peripheral T-Cell LymphomaPreclinical
CN
Axter Therapeutics (Beijing) Co., Ltd.
20 Jul 2023
Prostatic CancerPreclinical
CN
Axter Therapeutics (Tianjin) Co., Ltd.Axter Therapeutics (Tianjin) Co., Ltd.
19 Jul 2022
SarcomaPreclinical
CN
Axter Therapeutics (Tianjin) Co., Ltd.Axter Therapeutics (Tianjin) Co., Ltd.
19 Jul 2022
Stomach CancerPreclinical
CN
Axter Therapeutics (Tianjin) Co., Ltd.Axter Therapeutics (Tianjin) Co., Ltd.
19 Jul 2022
Follicular LymphomaPreclinical
US
Axter Therapeutics (Beijing) Co., Ltd.
30 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free